1/30
Looks like no tags are added yet.
Hallmarks of cancer original 6
sustaining proliferative signaling
evading growth supressors
resisting cell death
enabling replicative immortality
inducing angiogenesis
activating invasion and metastasis
Hallmarks additional 4
deregulating cellular metabolism
evading immune destruction
genome instability
tumor-promoting inflammation
Hallmarks extra 14
phenotypic plasticity & disrupted differentiation
nonmutational epigenetic reprogramming
polymorphic microbiomes
senescent cells in TME
cancer signaling regulates
proliferation, survival, differentiation, metabolism, migration
EGFR/HER2 in gastric cancer
crucial role in growth and spread of GC cells
PI3K/AKt/mTOR in gastric cancer
this pathway is activated due to gene mutations & is involved in tumoral activity
inhibitor classes against cancer pathways
small molecule inhibitors
monoclonal antibodies
immune checkpoint inhibitors
radioimmunotherapy
HER2 in breast cancer
HER2 is important because the signaling promotes :
receptor tyrosine kinase
some breast cancers have amplification.
proliferation, survival, tumor growth, therefore HER2 can become a therapeutic vulnerability.
epidermal growth factor receptors, HER family
what happens when growth factor binds?
all RTKs
receptor activation, receptor dimerization, tyrosine phosphorylation, intracellular signaling, cell proliferation/survival
trastuzumab/Herceptin
why is this useful?
monoclonal antibody targeting HER2
HER2 located on cell surface, antibody can bind extracellular. this then can interfere with signaling and can also recruit immune mechanisms against cancer cell.
Lapatinib
small molecule also important for HER2 signaling
cardiac toxicity of HER2
role in heart cells, so interference with HER2 can cause adverse effects such as cardiac dysfunction in some
cyclin dependent kinase inhibitors
most successful? target? what does it normally do?
effect of inhibitors?
CDK4/6. retinoblastoma protein. normally help control progression through cell cycle. CDK4/6 phosphorylates Rb. this releases E2F. transcription of S-phase genes increases. cell enters S-phase.
now, les Rb phosphorylation, E2F remains suppressed, S-phase entry decreased and cell proliferation is decreased.
this slows cancer proliferation
RAS/ERK/MAPK and Wnt pathways can promote abnormal signaling:
promote tumor development and stem-like properties.
mutations that keep components activated can promote uncontrolled growth
treatment resistance
cancer pathways are interconnected, inhibiting one pathway may not be enough
clonal selection/evolution
tumors are heterogeneic. some clones are sensitive while others aren't, and they survive and keep on growing.
oncogene addiction
cancer cell become heavily dependent on a single dominant oncogene
BCR-ABL in CML targeted by imatinib
EGFR activating mutations (exon 19 deletion) targeted by EGFR TKIs
HER2 amplification in BC, targeted by trastuzumab
KRAS G12C in lung/colon cancer, targeted by inhibitors
passenger mutations
often neutral, can accumulate
driver mutations
provide selective growth advantages
resistance to targeted therapies:
on-target and off-target/bypass resistance
on-target resistance
changes the drug target itself. like a change in the binding pocket, now the drug can’t bind effectively.
off-target/bypass resistance
cancer finds another way to achieve the same biological outcome
phenotypic plasticity
cancer cells can change their cellular identity/state without necessarily acquiring new DNA mutations. this can happen through epigenetic changes, transcriptional rewiring, altered chromatin accessibility.
resistance to targeted therapies
drug transport & metabolism. efflux pumps, drug inactivation/altered metabolism.
DNA damage repair and apoptosis pathways. restoration of HR (important for PARP inhibitors. tumor with BRCA mutation may be sensitive to PARP inhibition initially. but BRCA reversion mutation can restore HR. this way: DNA repair restored —> PARP inhibitor less effective), up regulation of anti-apoptotic proteins.
TME. hypoxia (reducing ROS-mediated killing and inducing HIF signaling), cancer associated fibroblasts secreting HGF which activates MET and bypasses EGFR inhibitor, immune evasion (up regulation of PD-L1 secretion of immunosuppressive cytokines)
secondary resistance mutations: imatinib
ATP pocket mutations: exon 13 (reduces drug binding affinity) and 14 (gatekeeper mutation, interferes with imatinib binding)
activation loop mutation: exon 17/18 (stabilize the kinase in its active conformation) imatinib binds inactive state so now it cannot bind anymore.
mechanisms of resistance for classical kinases:
gatekeeper mutations: change access to ATP pocket
ATP-pocket substitutions: change residues directly involved in drug binding
activation-loop stabilization: force the kinase toward an active conformation
gatekeeper mutation
normally, drug enters pocket, binds kinase, inhibits the kinase.
mutation, amino acid replaced with another residue that has different features. this way it interferes with inhibitor binding. ATP may still bind sufficiently for the kinase activity
examples ABL, where threonine gets changed for isoleucine
EGFR, where threonine gets changed for methionine
KIT, prevents imatinib binding
ATP-pocket substitution
amino acid lining the ATP binding region is altered. ATP might still bind, but the drug now cannot. this creates selective resistance to the drug
A-loop stabilization
the flexible region within a kinase.
different conformations: inactive (associated with DFG out)(A-loop positioned that it blocks substrate binding, gate closed) and active (associated with DFG in)(A-loop moves away, allowing binding, gate open).
DFG motif - Asp-Phe-Gly at the start of the loop. highly conserved in protein kinases.
example EGFR primarily inactive state. upon activation, undergoes transition from inactive monomeric form to active homoodimer.
—> this can cause therapy resistance
clinical strategies to overcome resistance
2nd and 3rd gen inhibitors.
synthetic lethality PARPi + BRCA1/2 mutation
BRCA1/2 mutation causes impairment in HR, but cell may still have other ways to repair DNA.
combining with PARPi, DNA damage accumulates and cancer cell dies.